All In Biotech

Drug Trial Radar · NCT00769067

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen

Last checked: Nov 20, 2026Latest source record: Oct 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Nov 2008

Primary completion

Oct 2010

Study completion Aug 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • ErlotinibDrug

    Continuous oral dosing at 150 mg daily.

  • PF-00299804Drug

    Continuous oral dosing at 45mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Baseline until disease progression or death, assessed at Cycle 2, 3, 4, 5, 6, thereafter every other cycle up to end of treatment (121 weeks), followed by every 8 weeks >284 weeks

Locations

59 sites in 12 countries. Site status is shown where the registry gives one.

  • Northwest Alabama Cancer Center

    Muscle Shoals, Alabama

  • Agajanian Institute of Oncology and Hematology

    Montebello, California

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • Wittingham Cancer Center @ Norwalk Hospital

    Norwalk, Connecticut

  • Medical Oncology & Hematology, P.C.

    Waterbury, Connecticut

  • Winship Cancer Institute at Grady Health Systems

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Augusta Oncology Associates, P.C.

    Augusta, Georgia

  • Augusta Oncology Associates, PC

    Augusta, Georgia

  • John B. Amos Cancer Center

    Columbus, Georgia

  • Georgia Cancer Specialists

    Decatur, Georgia

  • The Longstreet Cancer Center

    Gainesville, Georgia

  • Central Georgia Cancer Care, P.C.

    Macon, Georgia

  • Northwest Georgia Oncology Center

    Marietta, Georgia

  • Central Georgia Cancer Care, P.C.

    Warner Robins, Georgia

  • Kootenai Cancer Center at Post Falls

    Post Falls, Idaho

  • Kootenai Cancer Center

    Post Falls, Idaho

  • Midwestern Regional Medical Center

    Zion, Illinois

  • Center for Blood and Cancer Disorders

    Bethesda, Maryland

  • Associates in Oncology/Hematology, PC

    Rockville, Maryland

  • University of Minnesota Cancer Center

    Minneapolis, Minnesota

  • The West Clinic

    Memphis, Tennessee

  • Oncology/Hematology Associates

    Clarksburg, West Virginia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • St. Vincent's Hospital

    Fitzroy, Victoria, Australia

  • The Andrew Love Cancer Centre,

    Geelong, Victoria, Australia

  • Border Medical Oncology

    Wodonga, Victoria, Australia

  • Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • FUNDACAO PIO XII Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP

    São Paulo, São Paulo, Brazil

  • BC Cancer Agency - Vancouver Centre

    Vancouver, British Columbia, Canada

  • Royal Victoria Hospital

    Barrie, Ontario, Canada

  • RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Department of Clinical Oncology

    Shatin, New Territories, Hong Kong

  • Department of Clinical Oncology, Tuen Mun Hospital

    Tuenmen, New Territories, Hong Kong

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.